In recent years, ICB therapy, which targets PD-1/PD-L1 axis to unleash the killing ability of CD8+ T cells, has dramatically transformed the therapeutic paradigm for NSCLC [19]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.